Literature DB >> 17998901

Targeted genome modifications using integrase-deficient lentiviral vectors.

Tatjana I Cornu1, Toni Cathomen.   

Abstract

Gene correction aims at repairing a defective gene directly in the cellular genome, which warrants tissue-specific and sustained expression of the repaired gene through its endogenous promoter. We have developed a novel system based on integrase-deficient lentiviral vectors (IDLVs) that allows us to correct an endogenous mutation using a strategy based on homologous recombination (HR). In a proof-of-concept approach, an IDLV encoding a repair template was co-delivered with an I-SceI nuclease expression vector to rescue a defective enhanced green fluorescent protein (EGFP) gene. Expression of the nuclease created a double-strand break within the target locus, which was crucial for stimulating IDLV-based gene repair. Stable gene correction was realized in up to 12% of the cells, depending on the vector dose, the nuclease expression levels, and the cell type. Genotypic analyses confirmed that gene correction was the result of genuine HR between the target locus and the IDLV repair template. This study presents IDLVs as valuable tools for introducing precise and permanent genetic modifications in human cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17998901     DOI: 10.1038/sj.mt.6300345

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  52 in total

Review 1.  Zinc-finger nucleases for somatic gene therapy: the next frontier.

Authors:  Shamim H Rahman; Morgan L Maeder; J Keith Joung; Toni Cathomen
Journal:  Hum Gene Ther       Date:  2011-07-22       Impact factor: 5.695

Review 2.  Hybrid lentiviral vectors.

Authors:  Waseem Qasim; Conrad A Vink; Adrian J Thrasher
Journal:  Mol Ther       Date:  2010-04-20       Impact factor: 11.454

3.  Nonintegrating foamy virus vectors.

Authors:  David R Deyle; Yi Li; Erik M Olson; David W Russell
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

4.  Notable reduction in illegitimate integration mediated by a PPT-deleted, nonintegrating lentiviral vector.

Authors:  Boris Kantor; Matthew Bayer; Hong Ma; Jude Samulski; Chengwen Li; Thomas McCown; Tal Kafri
Journal:  Mol Ther       Date:  2010-12-14       Impact factor: 11.454

5.  Adenoviral vector DNA for accurate genome editing with engineered nucleases.

Authors:  Maarten Holkers; Ignazio Maggio; Sara F D Henriques; Josephine M Janssen; Toni Cathomen; Manuel A F V Gonçalves
Journal:  Nat Methods       Date:  2014-08-24       Impact factor: 28.547

Review 6.  Viral vectors for gene delivery to the central nervous system.

Authors:  Thomas B Lentz; Steven J Gray; R Jude Samulski
Journal:  Neurobiol Dis       Date:  2011-10-07       Impact factor: 5.996

Review 7.  Targeted gene therapies: tools, applications, optimization.

Authors:  Olivier Humbert; Luther Davis; Nancy Maizels
Journal:  Crit Rev Biochem Mol Biol       Date:  2012 May-Jun       Impact factor: 8.250

Review 8.  Viral manipulation of DNA repair and cell cycle checkpoints.

Authors:  Mira S Chaurushiya; Matthew D Weitzman
Journal:  DNA Repair (Amst)       Date:  2009-05-26

Review 9.  Integration-deficient lentiviral vectors: a slow coming of age.

Authors:  Klaus Wanisch; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2009-06-02       Impact factor: 11.454

10.  Expanding or restricting the target site repertoire of zinc-finger nucleases: the inter-domain linker as a major determinant of target site selectivity.

Authors:  Eva-Maria Händel; Stephen Alwin; Toni Cathomen
Journal:  Mol Ther       Date:  2008-11-11       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.